Pharma major Lupin today said that the Unites States Food & Drug Association (US FDA) inspected its Dabhasa facility between June 29 and July 6. Post the inspection, Form FDA 483 observations were issued by the regulator, which are minor in nature, the company said in a press release. The inspection has been classified as a Voluntary Action Indicated (VAI). It means that Lupin demonstrated corrective and preventive actions during the inspection to authorities. Dabhasa facility is an active pharmaceutical ingredient facility of the company. The company recently got a relief after receiving an Establishment Inspection Report (EIR) from US FDA for an inspection conducted in July 2015 in its Goa plant. At 13:14 hrs Lupin was quoting at Rs 1,638.05, down Rs 19.25, or 1.16 percent.
0 comments:
Post a Comment